NEC Corporation (NEC; TOKYO: 6701) acquired OncoImmunity AS, a Norway-based bioinformatics company that develops proprietary machine learning software to support the fight against cancer.
The amount of the deal was not disclosed.
Founded in 2014 and led by Dr. Richard Stratford, Chief Executive Officer, OncoImmunity is a bioinformatics company dedicated to the development of software solutions that facilitate the effective selection of patients for cancer immunotherapy, and identify optimal neoantigen targets for personalized cancer vaccines and cell therapies in a clinically actionable time frame.
OncoImmunity AS will now become a subsidiary of NEC and operate under the name of NEC OncoImmunity AS.
For NEC, the acquisition is integral for enhancing the resources and capabilities that support the development of its individualized immunotherapy pipelines. It will maintain its focus on drug discovery, while NEC OncoImmunity AS continues its neoantigen prediction services.